Comparison · NCT03005288-8d1fc7b4
BYM338 10 mg/kg vs Placebo: Immunogenicity Assessed by the Number of Participants Developing Anti-BYM338 Antibodies During the Trial
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. BYM338 10 mg/kg vs Placebo: Immunogenicity Assessed by the Number of Participants Developing Anti-BYM338 Antibodies During the Trial. Trial comparisons, record NCT03005288-8d1fc7b4. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03005288-8d1fc7b4
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0541 | 0.015 | 0.177 | wilson | |
| Risk in group 2 | 0.105 | 0.0417 | 0.241 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0512 | -0.193 | 0.0872 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.514 | 0.1 | 2.64 | log | |
| Odds ratio, group 1 over group 2 | 0.486 | 0.0834 | 2.83 | log | |
| Number needed to treat, for one fewer participant with the outcome on BYM338 10 mg/kg than on Placebo | 19.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | BYM338 10 mg/kg | intravenous infusion every four weeks | 2 | 37 | OG000 |
| Group 2 | Placebo | intravenous infusion every four weeks | 4 | 38 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Immunogenicity Assessed by the Number of Participants Developing Anti-BYM338 Antibodies During the Trial
- Description
Describes the number of participants tested positive for anti-BYM338 antibodies after the start of bimagrumab (BYM338) treatment. A validated bridging enzyme-linked immunosorbent assay (ELISA) was used for the confirmation of the presence of anti-BYM338 antibodies in human serum.
- Time frame
- 392 days
- Population
- Safety analysis set
Source ClinicalTrials.gov
Trial
- Title
- Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
- NCT number
- NCT03005288
- Phases
- PHASE2
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- BYM338 10 mg/kg, Placebo
- Lead sponsor
- Novartis Pharmaceuticals
- Results first posted
- 2020-06-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03005288?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03005288-8d1fc7b4